OR WAIT 15 SECS
July 15, 2015.
ANI Pharmaceuticals (Baudette, MN) has acquired 22 previously marketed generic drug products from Teva Pharmaceuticals for $25 million in cash and a percentage of future gross profits from product sales, IMS Health reports. The total market value for the 22 products is $650 million on a trailing 12-month basis.
Arthur S. Przybyl, President and CEO of ANI Pharmaceuticals, said the acquisition "meaningfully expands our product pipeline to 68 products with a total market value of $3.9B per IMS Health. We are pleased at the opportunity to extend our collaboration with Teva beyond the three transactions we have previously completed over the past 18 months."